30
Participants
Start Date
July 31, 2025
Primary Completion Date
August 1, 2027
Study Completion Date
August 1, 2028
Iparomlimab and Tuvonralimab
The administration regimen of Iparomlimab and Tuvonralimab is: the recommended dose of Iparomlimab and Tuvonralimab is 5mg/kg, intravenous infusion, with a treatment cycle of 21 days. The subjects will continue to receive treatment with Iparomlimab and Tuvonralimab until the termination criteria are met.
RECRUITING
the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
OTHER